

**A V E X A**

Avexa Limited
ABN 53 108 150 750
576 Swan Street Richmond
Victoria Australia 3121

Telephone 61 3 9208 4300
Facsimile 61 3 9208 4004
Website www.avexa.com.au

ASX Release

19 April 2007

AVX AUDIO BROADCAST

You are invited to a front row seat at our presentation titled “**Collaboration Agreement on HIV Drug Program**”, Conveniently, you don’t have to leave your home or office to attend.

To listen, simply click on the link below:

<http://www.brr.com.au/event/AVX/1243/22343/wmp/n4i0jtcnej>

Receive alerts on future announcements, click below.

[Boardroomradio Alerts](#)

The presentation details are as follows;

- **Collaboration Agreement on HIV Drug Program**
- **Presented By Dr Julian Chick, CEO**
- **Thursday 19 April 2007, 3.00PM AEST**

Access archived presentations on demand by visiting www.brr.com.au

Boardroomradio also offers a free Podcast subscription, check the website for details.

For more information:

Dr. Julian Chick
Chief Executive Officer
+61 3 9208 4300

Mr Rod North
Bourse Communications
+ 61 (03) 9510-8309

www.avexa.com.au

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases, in particular diseases which have a significant unmet medical need. Avexa has dedicated resources and funding for key projects including antiviral drugs for HIV and an antibiotic alternative for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC) which has recently successfully completed the 21 day dosing of its Phase IIb trial. The Company continues to progress ATC towards Phase III trials.